The tamoxifen dilemma

Carcinogenesis

Volumn 20, Issue 7, 1999, Pages 1153-1160

  White, Ian N H ^a  

^a MRC TOXICOLOGY UNIT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; DRUG METABOLIZING ENZYME; ESTROGEN RECEPTOR; TAMOXIFEN;

ANIMAL CELL; ANIMAL EXPERIMENT; CANCER RISK; CARCINOGENESIS; CONTROLLED STUDY; DNA DAMAGE; DRUG DNA BINDING; DRUG METABOLISM; DRUG STRUCTURE; ENDOMETRIUM CANCER; GENOTOXICITY; HUMAN; HUMAN CELL; ISOTOPE LABELING; LIVER CARCINOGENESIS; MASS SPECTROMETRY; METABOLIC ACTIVATION; MOUSE; NONHUMAN; NOTE; PRIORITY JOURNAL; RAT;

ANIMALS; ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; BIOTRANSFORMATION; BREAST NEOPLASMS; CARCINOGENS; DNA DAMAGE; DRUG DESIGN; ENDOMETRIAL NEOPLASMS; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; INCIDENCE; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MICE; RATS; RECEPTORS, ESTROGEN; RISK ASSESSMENT; TAMOXIFEN; UTERUS;

EID: 0032808213     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/20.7.1153     Document Type: Note

References (95)

1. Powles, T.J. and Hickish, T. (1995) Tamoxifen therapy and carcinogenic risk. J. Natl Cancer Inst., 87, 1343-1345.
2. Clarke, M., Collins, R., Davies, C., Godwin, J., Gray, R., Peto, R. and EBCTCG Secretariat (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet, 351, 1451-1467.
3. Poirier, D., Auger, S., Merand, Y., Simard, J. and Labrie, F. (1994) Synthesis and antiestrogenic activity of diaryl thioether derivatives. J. Med. Chem., 37, 1115-1125.
4. IARC (1996) Tamoxifen. In Some Pharmaceutical Drugs. IARC, Lyon, pp. 253-365.
5. Early Breast Cancer Trialist' Collaborative Group (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet, 339, 1-15.
6. Fisher, B., Costantino, J.P., Wickerham, D.L. et al. (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J. Natl Cancer Inst., 90, 1371-1388.
7. Powles, T., Eeles, R., Ashley, S., Easton, D., Chang, J., Dowsett, M., Tidy, A., Viggers, J. and Davey, J. (1998) Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet, 352, 98-101.
8. Veronesi, U., Maisonneuve, P., Costa, A., Sacchini, V., Maltoni, C., Robertson, C., Rotmensz, N. and Boyle, P. (1998) Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Lancet, 352, 93-97.
9. Blackwood, M.A. and Weber, B.L. (1998) BRCA1 and BRCA2: from molecular genetics to clinical medicine. J. Clin. Oncol., 16, 1969-1977.
10. Fornander, T., Cedermark, B., Mattsson, A. et al. (1989) Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet, 1, 117-119.
11. Rutqvist, L.E., Johansson, H., Signomklao, T., Johansson, U., Fornander, T. and Wilking, N. (1995) Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. J. Natl Cancer Inst., 87, 645-651.
12. Curtis, R.E., Boice, J.D. Jr, Shriner, D.A., Hankey, B.F. and Fraumeni, J.F. Jr (1996) Second cancers after adjuvant tamoxifen therapy for breast cancer. J. Natl Cancer Inst., 88, 832-834.
13. Jordan, V.C. (1998) Designer estrogens. Sci. Am., 279, 36-43.
14. Greaves, P., Goonetilleke, R., Nunn, G., Topham, J. and Orton, T. (1993) Two-year carcinogenicity study of tamoxifen in Alderly Park Wistar-derived rats. Cancer Res., 53, 3919-3924.
15. Williams, G.M., Iatropoulos, M.J., Djordjevic, M.V. and Kaltenberg, O.P. (1993) The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat. Carcinogenesis, 14, 315-317.
16. Hard, G.C., Iatropoulos, M.J., Jordan, K., Radi, L., Kaltenberg, O.P., Imondi, A.R. and Williams, G.M. (1993) Major differences in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Cr1:CD(BR) rats. Cancer Res., 53, 4534-4541.
17. Hirsimaki, P., Hirsimaki, Y., Nieminen, L. and Payne, B.J. (1993) Tamoxifen induces hepatocellular carcinoma in rat liver: a 1-year study with two antiestrogens. Arch. Toxicol., 67, 49-54.
18. Tucker, M.J., Adams, H.K. and Patterson, J.S. (1984) Tamoxifen. In Laurence, D.R., McLean, A.E.M. and Weatherall, M. (eds) Safety Testing of New Drugs. Academic Press, New York, NY, pp. 125-161.
19. Martin, E.A., Carthew, P., White, I.N.H., Heydon, R.T., Gaskell, M., Mauthe, R.J., Turteltaub, K.W. and Smith, L.L. (1997) Investigation of the formation and accumulation of liver DNA adducts in mice chronically exposed to tamoxifen. Carcinogenesis, 18, 2209-2215.
20. Carthew, P., Martin, E.A., White, I.N.H., De Matteis, F., Edwards, R.E., Dorman, B.M., Heydon, R.T. and Smith, L.L. (1995) Tamoxifen induces short-term cumulative DNA damage and liver tumors in rats: promotion by phenobarbital. Cancer Res., 55, 544-547.
21. Dragan, Y.P., Fahey, S., Street, K., Vaughan, J., Jordan, V.C. and Pitot, H.C. (1994) Studies of tamoxifen as a promoter of hepatocarcinogenesis in female Fischer F344 rats. Breast Cancer Res. Treat., 31, 11-25.
22. Carthew, P., Edwards, R.E. and Nolan, B.M. (1997) Depletion of hepatocyte nuclear estrogen receptor expression is associated with promotion of tamoxifen induced GST-P foci to tumours in rat liver. Carcinogenesis, 18, 1109-1112.
23. Newbold, R.R., Jefferson, W.N., PadillaBurgos, E. and Bullock, B.C. (1997) Uterine carcinoma in mice treated neonatally with tamoxifen. Carcinogenesis, 18, 2293-2298.
24. Han, X. and Liehr, J.G. (1992) Induction of covalent DNA adducts in rodents by tamoxifen. Cancer Res., 52, 1360-1363.
25. White, I.N.H., De Matteis, F., Davies, A., Smith, L.L., Crofton Sleigh, C., Venitt, S., Hewer, A. and Phillips, D.H. (1992) Genotoxic potential of tamoxifen and analogues in female Fischer F344/N rats, DBA/2 and C57BI/6 mice and in human MCL-5 cells. Carcinogenesis, 13, 2197-2203.
26. 32P-postlabelled DNA adducts by the development of a novel automated on-line solid-phase extraction HPLC method. Carcinogenesis, 19, 1061-1069.
27. 32P-postlabelling in three rat strains exposed to dietary tamoxifen: the relationship between cell proliferation and liver tumour formation. Carcinogenesis, 16, 1299-1304.
28. Li, D., Dragan, Y., Jordan, V.C., Wang, M. and Pitot, H.C. (1997) Effects of chronic administration of tamoxifen and toremifene on DNA adducts in rat liver, kidney and uterus. Cancer Res., 57, 1438-1441.
29. Montandon, F. and Williams, G.M. (1994) Comparison of DNA reactivity of the polyphenylethylene hormonal agents diethylstilbestrol, tamoxifen and toremifene in rat and hamster liver. Arch. Toxicol., 68, 272-275.
30. Pace, P., Jarman, M., Phillips, D., Hewer, A., Bliss, J. and Coombes, R.C. (1997) Idoxifene is equipotent to tamoxifen in inhibiting mammary Carcinogenesis but forms lower levels of hepatic DNA adducts. Br. J. Cancer, 76, 700-704.
31. Dahme, E. and Rattel, B. (1994) Unlike tamoxifen, droloxifene produces no hepatic tumors in the rat. Onkologie, 17, 6-16.
32. 14C]radiolabelled tamoxifen or toremifene to rat DNA using accelerator mass spectrometry. Chem. Biol. Interact., 106, 149-160.
33. Randerath, K., Bi, J., Mabon, N., Sriram, P. and Moorthy, B. (1994) Strong intensification of mouse hepatic lamoxifen DNA adduct formation by pretreatment with the sulfotransferase inhibitor and ubiquitous environmental pollutant pentachlorophenol. Carcinogenesis, 15, 797-800.
34. Davies, R., Oreffo, V.I.C., Bayliss, S., Dinh, P.-A., Lilley, K.S., White, I.N.H., Smith, L.L. and Styles, J.A. (1996) Mutational spectra of tamoxifen-induced mutations in the livers of lad transgenic rats. Environ. Mol. Mutagen., 28, 430-433.
35. Davies, R., Oreffo, V.I.C., Martin, E.A., Festing, M., White, I.N.H., Smith, L.L. and Styles, J.A. (1997) Tamoxifen causes gene mutations in the livers of lambda/lacI transgenic rats. Cancer Res., 57, 1288-1293.
36. Vancutsem, P.M., Lazarus, P. and Williams, G.M. (1994) Frequent and specific mutations of the rat p53 gene in hepatocarcinomas induced by tamoxifen. Cancer Res., 54, 3864-3867.
37. Hsu, I.C., Meetcalf, R.A., Sun, T., Welsh, J.A., Wang, N.J. and Harris, C.C. (1991) Mutational hot spot in the p53 gene in human hepatocellular carcinomas. Nature, 350, 427-428.
38. Bressac, B., Khalid, S., Wands, J. and Ozturk, M. (1991) G to T mutations of p53 gene in hepatocellular carcinomas from Southern Africa. Nature, 350, 429-432.
39. Welsh, J.A., Moberger, B., Fornander, T. et al. (1997) Tamoxifen has a characteristic mutation spectrum in human endometrial cancers. Proc. Am. Soc. Cancer Res., 38, 450.
40. Kuwashima, Y., Kurosumi, M., Kobayashi, Y., Tanuma, J., Suemasu, K., Higashi, Y., Kasamatsu, T., Shiromizu, K. and Kishi, K. (1998) Random nuclear p53 overexpression pattern in tamoxifen-mediated endometrial carcinoma. Int. J. Gynecol. Pathol., 17, 135-139.
41. Lim, C.K., Yuan, Z., Lamb, J.H., White, I.N.H., De Matteis, F. and Smith, L.L. (1994) A comparative study of tamoxifen metabolism in female rat, mouse and human liver microsomes. Carcinogenesis, 15, 589-593.
42. Reunitz, P.C., Bagley, J.R. and Pape, C.W. (1984) Some chemical and biochemical aspects of liver microsomal metabolism of tamoxifen. Drug Metab. Dispos., 12, 478-483.
43. Jones, R.M., Yuan, Z.X., Lamb, J.H. and Lim, C.K. (1996) On-line high-performance liquid chromatographic - electrospray ionization mass spectrometric method for the study of tamoxifen metabolism. J. Chromatogr., 722A, 249-255.
44. Boocock, D.J., Maggs, J.L., White, I.N.H. and Park, B.K. (1999) α-Hydroxytamoxifen, a genotoxic metabolite of tamoxifen in the rat: identification and quantification in vivo and in vitro. Carcinogenesis, 20, 153-160.
45. Jacolot, F., Simon, I., Dreano, Y., Beaune, P., Riche, C. and Berthou, F. (1991) Identification of the cytochrome P450 IIIA family as the enzymes involved in the N-demethylation of tamoxifen in human liver microsomes. Biochem. Phamacol., 41, 1911-1919.
46. Berthou, F., Dreano, Y., Belloc, C., Kangas, L., Gautier, J.C. and Beaune, P. (1994) Involvement of cytochrome P450 3A enzyme family in the major metabolic pathways of toremifene in human liver microsomes. Biochem. Pharmacol., 47, 1883-1895.
47. Dehal, S.S. and Kupfer, D. (1997) CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver. Cancer Res., 57, 3402-3406.
48. Crewe, H.K., Ellis, S.W., Lennard, M.S. and Tucker, G.T. (1997) Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes. Biochem. Pharmacol., 53, 171-178.
49. Styles, J.A., Davies, A., Lim, C.K., De Matteis, F., Stanley, L.A., White, I.N.H., Yuan, Z.X. and Smith, L.L. (1994) Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. Carcinogenesis, 15, 5-9.
50. Mani, C., Pearce, R., Parkinson, A. and Kupfer, D. (1994) Involvement of cytochrome P4503A in catalysis of tamoxifen activation and covalent binding to rat and human liver microsomes. Carcinogenesis, 15, 2715-2720.
51. 14C]tamoxifen to liver microsomes and the forms of cytochrome P450 involved. Biochem. Pharmacol., 49, 1035-1042.
52. Birnboim, H.C. (1985) DNA clastogenic activity of diethylstilbestrol. Biochem. Pharmacol., 34, 3251-3257.
53. Phillips, D.H., Carmichael, P.L., Hewer, A., Cole, K.J. and Poon, G.K. (1995) α-Hydroxytamoxifen, a metabolite of tamoxifen with exceptionally high DNA binding activity in rat hepatocytes. Cancer Res., 54, 5518-5522.
54. Potter, G.A., McCague, R. and Jarman, M. (1994) A mechanistic hypothesis for DNA adduct formation by tamoxifen following hepatic oxidative metabolism. Carcinogenesis, 15, 439-442.
55. Poon, G.K., Walter, B., Lonning, P.E., Horton, M.N. and McCague, R. (1995) Identification of tamoxifen metabolites in human HEP G2 cell line, human liver homogenate and patients on long-term therapy for breast cancer. Drug Metab. Dispos., 23, 377-382.
56. Phillips, D.H., Potter, G.A., Horton, M.N., Hewer, A., Crofton Sleigh, C., Jarman, M. and Venitt, S. (1994) Reduced genotoxicity of [D5-ethyl]-tamoxifen implicates α-hydroxylation of the ethyl group as a major pathway of tamoxifen activation to a liver carcinogen. Carcinogenesis, 15, 1487-1492.
57. Davis, W., Venitt, S. and Phillips, D.H. (1998) The metabolic activation of tamoxifen and alpha-hydroxytamoxifen to DNA-binding species in rat hepatocytes proceeds via sulphation. Carcinogenesis, 19, 861-866.
58. Osborne, M.R., Hewer, A., Hardcastle, I.R., Carmichael, P.L. and Phillips, D.H. (1996) Identification of the major tamoxifen - deoxyguanosine adduct formed in the liver DNA of rats treated with tamoxifen. Cancer Res., 56, 66-71.
59. Dasaradhi, L. and Shibutani, S. (1997) Identification of tamoxifen - DNA adducts formed by α-sulfate tamoxifen and α-acetoxytamoxifen. Chem. Res. Toxicol., 10, 189-196.
60. Osborne, M.R., Hardcastle, I.R. and Phillips, D.H. (1997) Minor products of reaction of DNA with α-acetoxytamoxifen. Carcinogenesis, 18, 539-543.
61. Shibutani, S., Dasaradhi, L., Terashima, I., Banoglu, E. and Duffel, M.W. (1998) Alpha-hydroxytamoxifen is a substrate of hydroxysteroid (alcohol) sulfotransferase, resulting in tamoxifen DNA adducts. Cancer Res., 58, 647-653.
62. Dipple, A. (1995) DNA adducts of chemical carcinogens. Carcinogenesis, 16, 437-441.
63. Lim, C.K., Yuan, Z.X., Jones, R.M., White, I.N.H. and Smith, L.L. (1998) Identification and mechanism of formation of potentially genotoxic metabolites of tamoxifen: study by LC-MS/MS. J. Pharm. Biomed. Anal., 15, 1335-1342.
64. Moorthy, B., Sriram, P., Pathak, D.N., Bodell, W.J. and Randerath, K. (1996) Tamoxifen metabolic activation: comparison of DNA adducts formed by microsomal and chemical activation of tamoxifen and 4-hydroxytamoxifen with DNA adducts formed in vivo. Cancer Res., 56, 53-57.
65. Davies, A.M., Martin, E.A., Jones, R.M., Lim, C.K., Smith, L.L. and White, I.N.H. (1995) Peroxidase activation of tamoxifen and toremifene resulting in DNA damage and covalently bound protein adducts. Carcinogenesis, 16, 539-545.
66. Davies, A.M., Malone, M.E., Martin, E.A., Jones, R.M., Jukes, R., Lim, C.K., Smith, L.L. and White, I.N.H. (1997) Peroxidase activation of 4-hydroxytamoxifen to free radicals detected by EPR spectroscopy. Free Radic. Biol. Med., 22, 423-431.
67. Dehal, S.S. and Kupfer, D. (1996) Evidence that the catechol 3,4-dihydroxytamoxifen is a proximate intermediate to the reactive species binding covalently to proteins. Cancer Res., 56, 1283-1290.
68. 32P-postlabelled DNA adducts in liver obtained from women treated with tamoxifen. Carcinogenesis, 16, 1651-1654.
69. Phillips, D.H., Hewer, A., Grover, P.L., Poon, G.K. and Carmichael, P.L. (1996) Tamoxifen does not form detectable DNA adducts in white blood cells of breast cancer patients. Carcinogenesis, 17, 1149-1152.
70. Shibutani, S., Shaw, P.M., Suzuki, N., Dasaradhi, L., Duffel, M.W. and Terashima, I. (1998) Sulfation of α-hydroxytamoxifen catalyzed by human hydroxysteroid sulfotransferase results in tamoxifen - DNA adducts. Carcinogenesis, 19, 2007-2011.
71. Carmichael, P.L., Ugwumadu, A.H.N., Neven, P., Hewer, A.J., Poon, G.K. and Phillips, D.H. (1996) Lack of genotoxicity of tamoxifen in human endometrium. Cancer Res., 56, 1475-1479.
72. Carmichael, P.L., Neven, P., Sardar, S. et al. (1998) A lack of evidence for the genotoxicity of tamoxifen and toremifene in the human endometrium. Eur. J. Cancer, 34, P106.
73. Hemminki, K., Rajaniemi, H., Lindahl, B. and Moberger, B. (1996) Tamoxifen-induced DNA adducts in endometrial samples from breast cancer patients. Cancer Res., 56, 4374-4377.
74. Fisher, B., Costantino, J.P., Redmond, C.K., Fisher, E.R., Wickerham, D.L., Cronin, W.M. and NSABP Contributors (1994) Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J. Natl Cancer Inst., 86, 527-537.
75. White, I.N.H., Gibbs, A.H., Jones, A.M., Lim, C.K., Al-Azzawi, F. and Smith, L.L. (1997) Comparison of the potential of microsomal fraction from human and rat reproductive tracts to activate tamoxifen. Proc. Am. Soc. Cancer Res., 38, 337
76. Styles, J.A., Davies, A., Davies, R., White, I.N.H. and Smith, L.L. (1997) Clastogenic and aneugenic effects of tamoxifen and some of its analogues in hepatocytes from dosed rats and in human lymphoblastoid cells transfected with human P450 cDNAs (MCL-5 cells). Carcinogenesis, 18, 303-313.
77. Sargent, L.M., Dragan, Y.P., Sattler, C. et al. (1996) Induction of hepatic aneuploidy in vivo by tamoxifen, toremifene and idoxifene in female Sprague-Dawley rats. Carcinogenesis, 17, 1051-1056. [Erratum, Carcinogenesis (1996), 17, 1393.]
78. Pathak, D.N. and Bodell, W.J. (1994) DNA adduct formation by tamoxifen with rat and human liver microsomal activation systems. Carcinogenesis, 15, 529-532.
79. Wakeling, A.E. and Bowler, J. (1992) ICI 182 780, a new antioestrogen with clinical potential. J. Steroid Biochem. Mol. Biol., 43, 173-177.
80. Wakeling, A.E. (1993) Are breast tumours resistant to tamoxifen also resistant to pure antioestrogens? J. Steroid Biochem. Mol. Biol., 47, 107-114.
81. Wakeling, A.E. (1995) Tissue-specific actions of antioestrogens. Mutat. Res. Fundam. Mol. Mech. Mutagen., 333, 45-49.
82. Martel, C., Labrie, C., Belanger, A., Gauthier, S., Merand, Y., Li, X., Provencher, L., Candas, B. and Labrie, F. (1998) Comparison of the effects of the new orally active antiestrogen EM-800 with ICI 182 780 and toremifene on estrogen-sensitive parameters in the ovariectomized mouse. Endocrinology, 139, 2486-2492.
83. Howell, A., DeFriend, D.J., Robertson, J.F.R., Blamey, R.W., Anderson, L., Anderson, E., Sutcliffe, F.A. and Walton, P. (1996) Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182 780 in women with advanced breast cancer. Br. J. Cancer, 74, 300-308.
84. Robertson, J.F.R., Howell, A., DeFriend, D.J., Blamey, R.W., Walton, P. and De Friend, D.J. (1997) Duration of remission to ICI 182 780 compared to megestrol acetate in tamoxifen resistant breast cancer. Breast, 6, 186-189.
85. Delmas, P.D., Bjarnason, N.H., Mitlak, B.H., Ravoux, A.C., Shah, A.S., Huster, W.J., Draper, M., Christiansen, C. and Ravoux, A.-C. (1997) Effects of raloxifene on bone mineral density, serum cholesterol concentrations and uterine endometrium in postmenopausal women. N. Engl. J. Med., 337, 1641-1647.
86. Jordan, V.C. (1998) Antiestrogenic action of raloxifene and tamoxifen: today and tomorrow. J. Natl Cancer Inst., 90, 967-971.
87. Frolik, C.A., Bryant, H.U., Black, E.C., Magee, D.E. and Chandrasekhar, S. (1996) Time-dependent changes in biochemical bone markers and serum cholesterol in ovariectomized rats: effects of raloxifene hcl, tamoxifen, estrogen and alendronate. Bone, 18, 621-627.
88. Boss, S.M., Huster, W.J., Neild, J.A., Glant, M.D., Eisenhut, C.C. and Draper, M.W. (1997) Effects of raloxifene hydrochloride on the endometrium of postmenopausal women. Am. J. Obstet. Gynecol., 177, 1458-1464.
89. Ashby, J., Odum, J. and Foster, J.R. (1997) Activity of raloxifene in immature and ovariectomized rat uterotrophic assays. Regul. Toxicol. Pharmacol., 25, 226-231.
90. Yang, N.N., Venugopalan, M., Hardikar, S. and Glasebrook, A. (1996) Identification of an estrogen response element activated by metabolites of 17β-estradiol and raloxifene. Science, 273, 1222-1225.
91. Brzozowski, A.M., Pike, A.C.W., Dauter, Z. et al. (1997) Molecular basis of agonism and antagonism in the oestrogen receptor. Nature, 389, 753-758.
92. Levenson, A.S. and Jordan, V.C. (1998) The key to the antiestrogenic mechanism of raloxifene is amino acid 351 (aspartate) in the estrogen receptor. Cancer Res., 58, 1872-1875.
93. Barkhem, T., Carlsson, B., Nilsson, Y., Enmark, E., Gustafsson, J.A., Nilsson, S. and Gustafsson, J.-A. (1998) Differential response of estrogen receptor alpha and estrogen receptor beta to partial estrogen agonists/ antagonists. Mol. Pharmacol., 54, 105-112.
94. Paech, K., Webb, P., Kuiper, G.G.J.M., Nilsson, S., Gustafsson, J.Å., Kushner, P.J., Scanlan, T.S. and Gustafsson, J.-A. (1997) Differential ligand activation of estrogen receptors er alpha and er beta at ap1 sites. Science, 277, 1508-1510.
95. Martin, E.A., Gaskell, M., White, I.N.H. et al (1998) Analysis of tamoxifen -DNA adducts in humans and rats by accelerator mass spectrometry. Mutagenesis, 13, 528, abstract 29.